adjuvant chemotherapy increases survival of oesophageal cancer patients has been widely debated. The present study used meta-analysis software to combine data from six studies up to July 2007 that were found and selected as suitable, comprising a total of 1001 oesophageal cancer patients. The results indicated that adjuvant chemotherapy did not significantly improve outcome in oesophageal cancer patients. A trend towards improved outcome from adjuvant chemotherapy was found in lymph node-positive patients, but did not reach significance. In our own study including 270 oesophageal cancer patients, adjuvant chemotherapy did not improve overall patient survival, but did improve survival for patients with metastases in cervical and/or celiac lymph nodes (stage IVa). Although our study had the largest patient sample, more prospective clinical trials with large numbers of patients are necessary to confirm the value of adjuvant chemotherapy in stage IVa patients.
Introduction
Carcinoma of the oesophagus and gastrooesophageal junction is an aggressive disease with a poor prognosis. It is the second most common cause of cancer-related deaths in women and the fourth in men in China. 1 Although surgical oesophagectomy remains the primary treatment for clinically localized thoracic oesophageal carcinoma, there is increasing enthusiasm for multidisciplinary treatment modality to improve outcome.
In the 1990s, no survival benefit for postoperative chemotherapy in oesophageal cancer was shown in three small-sample randomized clinical trials. 2 -4 However, some data showed that adjuvant chemotherapy might prolong disease-free survival (DFS) or improve treatment outcome in oesophageal cancer. 5, 6 In the 2000s, there has been increasing evidence. The Japan Clinical Oncology Group Study (JCOG 9204) 7 showed that post-operative chemotherapy can significantly increase 5-year DFS, but not overall survival (OS) in oesophageal cancer patients; the effect was marked in the subgroup with lymph node metastasis. Lee et al. 8 reported that the 3-year DFS rate was 47.6% in a group given adjuvant J Zhang, H-Q Chen, Y-W Zhang et al. Adjuvant chemotherapy in oesophageal cancer chemotherapy compared with 35.6% in the control group (P = 0.049) for lymph nodepositive thoracic oesophageal squamous cell carcinoma. Another study from Japan showed long-term post-operative treatment with low-dose cisplatin (CDDP) plus 5fluorouracil (5-FU) was therapeutically beneficial and prolonged survival in patients with regional lymph node metastasis or lymphatic invasion, or stage III disease. 9 To elucidate the role of adjuvant chemotherapy in oesophageal cancer and to guide future clinical practice, the current meta-analysis combined data from all relevant studies in English language publications up to July 2007. The survival rates of patients at the Shanghai Cancer Hospital who received adjuvant chemotherapy of cisplatin and 5-FU plus leucovorin were also compared with those who did not receive this regimen. The majority of patients underwent three-field lymphadenectomy.
Patients and methods

META-ANALYSIS DATA GATHERING
The resources used for the current metaanalysis were PubMed, American Society of Clinical Oncology (ASCO) abstracts and CancerLit. Key words used in the search were 'oesophageal neoplasms' and 'adjuvant chemotherapy'. For the identified papers, related articles provided by PubMed and papers listed in the references were further reviewed to identify additional publications. The analysed data covered those reported in English language publications up to July 2007. When exact survival rates were not available we: (i) contacted the corresponding author to obtain the survival rates of subgroups 8 ; or (ii) used survival curves to obtain survival rates at some time points, as previously reported 10, 11 (although we recognize this is a suboptimal method). Data extraction from survival curves was performed by two researchers independently.
SHANGHAI CANCER HOSPITAL EXPERIENCE
Patients
All patients included in the study had been referred for surgical treatment at Shanghai Cancer Hospital, Fudan University between 1998 and 2004. They were categorized into two groups according to whether or not they received post-operative adjuvant chemotherapy. Patients received either transthoracic oesophagectomy with threefield lymphadenectomy or two-field lymph node dissection (including the lymph nodes along the recurrent nerve). The bilateral supraclavicular lymph nodes and those along the recurrent nerve were removed in three-field lympadenectomy. Oesophageal reconstruction was performed using the stomach, via the oesophageal bed or retrosternal route.
Patient inclusion criteria were: (i) confirmation of oesophageal cancer by histology; (ii) pathological stages I, IIa, IIb, III or IVa due to distant node involvement (M1 lymph) only; (iii) baseline laboratory tests, i.e. white blood cell count > 4.0 × 10 9 /l, platelet count > 100 × 10 9 /l, adequate renal function (alanine aminotransferase and aspartate aminotransferase within normal levels); (iv) Karnofsky performance status > 70; (v) within 7 weeks post-operation; (vi) no prior antitumour therapy; and (vii) no serious medical conditions that would preclude safe administration of treatment.
Patients or their legal representatives signed a patient consent form prior to treatment being given.
Chemotherapy and follow-up
Chemotherapy comprised cisplatin 25 mg/m 2 daily from day 1 to 3, and 5-FU 375 J Zhang, H-Q Chen, Y-W Zhang et al.
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mg/m 2 and leucovorin 135 mg/m 2 daily from day 1 to 5, every 3 weeks. Four to six cycles of chemotherapy were planned. Toxicity during chemotherapy was evaluated and managed by the oncologists.
After treatment, patients were followed-up every 4 months for the first year, every 6 months for the next 2 years, and then annually thereafter. This was undertaken either as outpatients or by letter or telephone interview by a full-time senior nurse. The patients remaining alive were followed-up again prior to the start of this analysis.
DATA AND STATISTICAL ANALYSES
The meta-analysis was conducted using Comprehensive Meta-analysis software downloaded from www.meta-analysis.com (Biostat Inc., Englewood, NJ, USA). A Q-test was performed to assess possible heterogeneity between the individual studies. Where heterogeneity existed, a random effects model was adopted; otherwise both fixed effects and random models were deemed appropriate.
Patient survival curves were calculated according to the Kaplan-Meier method and compared by the log-rank test. The OS rate was estimated using life tables. Frequencies were compared using crosstabs and the χ 2 test for qualitative variables. The Cox proportional hazards model was used for multivariate analysis. A P-value < 0.05 was considered to be statistically significant.
Results
META-ANALYSIS
Up to July 2007 only six studies comprising a total of 1001 oesophageal cancer patients could be found and were selected for the current meta-analysis. The Q-test indicated heterogeneity between the individual studies (Q = 13.268, P = 0.021) and, therefore, the random effects model was adopted to calculate odd ratios (OR). The overall OR for adjuvant chemotherapy was 0.961 (95% confidence interval [CI] 0.741 -1.246; not statistically significant); detailed results are shown in Table 1 .
The significance of adjuvant chemotherapy in lymph node-positive patients was further investigated and four of the original six studies were identified for analysis. There was no significant Using a fixed effects model, meta-analysis of these four studies showed a trend towards a better outcome from adjuvant chemotherapy in lymph node-positive patients, although this was not statistically significant (overall OR of 0.763 in favour of adjuvant chemotherapy; 95% CI 0.538 -1.083; not statistically significant) ( Table 2 ).
SHANGHAI CANCER CENTRE EXPERIENCE
Patients
Baseline clinical and pathological factors for the oesophageal cancer patients treated with (n = 90) or without (n = 180) post-operative adjuvant chemotherapy, including age, gender, tumour location, TNM (tumour, node, metastasis) stage and surgical methods were comparable between the two groups and are shown in Table 3 . The ages of the patients ranged from 30 to 77 years, with a mean age of 53.81 years for the chemotherapy group and 56.06 years for the non-chemotherapy group. Four to six cycles of chemotherapy were intended and 66 (73.3%) patients received the planned schedule. The patients experienced mild-to-moderate common acute and late toxicity to chemotherapy although, generally, the treatment was well tolerated and there was no treatment-induced mortality.
In stage IVa, 14 out of 22 patients were of pathological stage T1 or T2, and 18 had lymph node metastasis limited to the cervical or celiac lymph node.
DFS and OS by adjuvant treatment modality
For the entire population studied, neither adjuvant chemotherapy nor radiation therapy improved DFS and OS. Similar treatment outcomes were found in terms of DFS and OS when the following adjuvant treatment modalities were compared: combination of chemotherapy and radiation therapy; chemotherapy alone; radiation therapy alone; and no adjuvant treatment (3-year DFS 45.0%, 34.4%, 50.0% and 46.3%, respectively, and 3-year OS 45.0%, 51.3%, 57.1% and 47.0%, respectively).
DFS and OS by pathological stage
In terms of pathological stage, both DFS and OS showed no significant differences for stages I, II and III between patients with and (Table 4 ). On the other hand, patients who had metastasis in the cervical and/or celiac lymph nodes (stage IVa) and received postoperative chemotherapy had a much better outcome compared with patients in the other stages (1-year DFS/OS 100%/100%, 3-year DFS/OS 75%/100%). The 1-and 3-year DFS and OS rates were significantly better for patients who received post-operative chemotherapy than for patients who did not receive it (DFS P = 0.038; OS P = 0.01; Table 4 ). 
Without adjuvant
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In the multivariate study using the Cox regression model, it was also found that adjuvant chemotherapy was an independent good prognostic factor in stage IVa patients.
Discussion
In western countries, pre-operative chemotherapy and chemoradiation therapy can increase OS by 4.4% and 6.4%, respectively, however, treatment-related mortality increases by 1.7% with neoadjuvant chemotherapy and by 3.4% with chemoradiotherapy, compared with surgery alone. 13 -17 In eastern countries, including Japan and China, many physicians prefer to delay administration of chemotherapy or chemoradiation therapy until post-operation. 18 Until now, no meta-analysis had exclusively studied the role of adjuvant chemotherapy in oesophageal cancer. The only related meta-analysis that had been performed was by the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. 2 They selected three studies, but one could not be included in the pooled analysis because the abstract did not report 3-year survival. No significant difference in the risk of mortality at 3 years for post-operative chemotherapy compared with surgery alone was found (relative risk 0.94; 95% CI 0.74 -1.18; not statistically significant). Since this meta-analysis on adjuvant treatment in oesophageal cancer was published several years ago, there has been a renewed enthusiasm for the investigation of chemotherapy in oesophageal cancer and a considerable number of new studies have been reported. It is, therefore, now timely to undertake a major update and re-evaluation of adjuvant chemotherapy in oesophageal cancer.
The present meta-analysis indicated that adjuvant chemotherapy did not improve the outcome of oesophageal cancer patients. A trend towards better outcome from adjuvant chemotherapy in lymph node-positive patients was detected, but the difference did not reach significance. Considering the heterogeneities of the studies and the bias of the meta-analysis, with the studies spanning one decade and the type of surgery varying from one study to another, our conclusions are tempered at present. Comparisons with control groups were also varied: for example, Lee et al. 8 used an historical control, whereas Ando et al. 7 was a multicentre randomized controlled trial. Additionally, no individual patient data were available to enhance the meta-analysis and possible differences in statistical methods may also have influenced it. More clinical trials with larger sample sizes are, therefore, necessary to elucidate the value of adjuvant chemotherapy in lymph node metastasis patients.
In the present study involving patients at Shanghai Cancer Hospital, the survival of patients with stages I, II and III disease who received adjuvant chemotherapy was similar to those did not receive chemotherapy. Adjuvant chemotherapy was most effective for patients who had metastasis in the cervical and/or celiac lymph nodes and significantly improved the treatment results of stage IVa patients. As this was a retrospective analysis, it had some advantages compared with other randomized clinical trials. First, three-field lymphadenectomy was performed on the majority of patients and the cervical-thoracic lymph nodes along the recurrent nerve and celiac lymph nodes were also dissected in a two-field oesophagectomy. Although threefield lymphadenectomy has not been the standard of care worldwide, it does provide improved staging. The patients in the present study could, therefore, be classified according to their cervical and/or celiac lymph node metastasis, thereby identifying those most likely to benefit from adjuvant chemotherapy. In the study by Lee et al., 8 only 10% of patients received three-field lymphadenectomy. In the other studies selected for the meta-analysis, although three-field lymphadenectomy was one of the surgical procedures, the survival of patients with cervical and/or celiac lymph node-positive (stage IVa) was not calculated. Secondly, in our clinical practice setting, the chemotherapy schedule that we used worked well with Chinese patients: four to six cycles of chemotherapy were suggested for the oesophageal cancer patients and 73.3% of patients received the planned schedule. The dose intensity was similar to that of the Japanese and French studies 3,7 mentioned above, but total dose was larger than in the Japanese study (two cycles) and smaller than in the French study (8 -10 cycles) . Thirdly, the current study had a larger patient sample compared with other studies published.
It is important to remain cautious about the current finding that adjuvant chemotherapy can significantly improve the prognosis of stage IVa patients. In the present study, 14 out of 22 stage IVa patients were pathological T1 or T2, and 18 had lymph node metastasis limited to the cervical or celiac lymph node. It is likely that patients with metastatic disease confined only to the cervical or celiac lymph node can survive longer than expected, and achieve more benefit from adjuvant chemotherapy.
